Visible Alpha BioPharma
Overview
Trusted by leading banks and investors, Visible Alpha BioPharma goes beyond consensus estimates to reveal the underlying assumptions driving drug- and market-level forecasts—helping you uncover insights, assess risk, and make more confident decisions across the biotech and pharmaceutical landscape.
Quantifying the Market View for Drugs
Deeper Competitive Intelligence
BioPharma's consensus data allows you to see how the market expects the competitive landscape will evolve over time, with forecasts extending out to 2035
Accurate Market Sizing
BioPharma provides a bottom-up consensus view of market sizing for drug indications, geographies, therapeutic areas, and mechanisms of action (MOA), driven by the granularity of our consensus data.
Flexible Data Delivery
BioPharma is available in the Insights web app, the Excel Add-In, via Visible Alpha Data Services (API, Data Feed, and Snowflake), and in S&P Capital IQ Pro allowing you to use our data in your preferred format.
How it Works
Scan Across a Universe of Drugs for a Robust Commercial View
When looking for differentiated opportunities, being armed with unbiased, data-driven insights is critical. Visible Alpha BioPharma’s homepage enables powerful, customizable search and visualization capabilities through our Search Bar, Filter Menu, and Charts Panels, revealing drug-level insights at a depth and breadth that has never before been possible.
Screen through our universe of over 6,300 drugs to reveal consensus estimates by indication, geography, clinical phase, MOA, commercial status, therapeutic area, target, drug class, company, and more, all powered by the latest sell-side models.
Instantly Uncover a Drug’s Core Attributes and Sales Data
Understand the Assumptions Behind Drug Revenue Builds
Visible Alpha BioPharma Highlights
Unprecedented Granularity
The BioPharma database includes consensus data on 6,300+ marketed and pipeline drugs, 1,000+ indications, 1,200+ MOAs, plus over 160 line items per company.
Data You Can Trust
While traditional vendors rely solely on research reports, all estimates in BioPharma are sourced directly from the full working models of over 260 contributing brokers, offering a more objective view.
All-in-One Interface
Within BioPharma, you can filter drugs by 20+ attributes for more comprehensive analysis, including forward-looking financials, parent company, clinical trial phase, indication, and MOA.
Longer Forecast Horizons
BioPharma makes long-term forecasting easier by providing consensus estimates as far out as 2040 and beyond on numerous drugs.
Gross and Risk-Adjusted Estimates
BioPharma enables you to view both gross and risk-adjusted revenue projections separately, giving you a fuller picture on any drug’s expected performance.
Consistently Up to Date
Any time an update is made to a contributing broker’s estimates, Visible Alpha aims to have this update reflected in-app within 24 hours (on average), ensuring you always have the latest data.
Support
Request Follow Up
Experience for yourself how Visible Alpha BioPharma helps pharmaceutical and biotech companies and investors unlock powerful insights on over 6,300 drugs.